ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - What's Next?

Key Points

• ArriVent’s Phase 3 FURVENT trial failed to meet its primary progression-free-survival endpoint in previously untreated EGFR exon 20 insertion-mutated non-small cell lung cancer, casting doubt on firmonertinib’s approval prospects and future development.
• The announcement triggered a trading halt and sharp selloff to a new one-year low, while trading volume rose 9% to 685,107 shares. Shareholders also face potential legal and financing overhangs following a pending investigation and the company’s recent $250 million at-the-market offering.
• Analysts have lowered price targets but remain broadly positive, with eight Buy ratings, one Hold, and one Sell; the consensus rating is “Moderate Buy” with an average target of $33.12.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) shares saw unusually-high trading volume on Wednesday. 685,107 shares changed hands during trading, an increase of 9% from the previous session's volume of 625,904 shares. The stock last traded at $16.0720 and had previously closed at $15.09.

Trending Headlines about ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Negative Sentiment: ArriVent announced that the Phase 3 FURVENT trial of firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer failed to meet its primary endpoint of progression-free survival, as assessed by blinded independent central review. The result raises substantial doubts about the drug’s approval prospects in this indication. ArriVent FURVENT trial update
• Negative Sentiment: The failed trial involves ArriVent’s lead clinical asset, prompting reports that the company is reassessing its plans for firmonertinib and resetting its investment case. The setback could lead to delays, additional development costs, or reduced investment in the program. ArriVent reviews firmonertinib plans
• Negative Sentiment: The announcement triggered a temporary trading halt and a sharp selloff, with AVBP reaching a new one-year low. The reaction reflects investors’ concerns over the company’s reduced pipeline value and uncertain path forward. ArriVent shares decline after FURVENT failure
• Negative Sentiment: Levi & Korsinsky announced a pending investigation into ArriVent following the stock decline. The notice highlights that shareholders were holding the stock near a 52-week low after the failed trial and notes the company had launched a $250 million at-the-market offering roughly five months earlier, adding potential legal and financing overhang. ArriVent investigation notice

Wall Street Analyst Weigh In

AVBP has been the topic of several recent research reports. Cantor Fitzgerald restated an "overweight" rating on shares of ArriVent BioPharma in a research report on Tuesday, September 22nd. BTIG Research decreased their target price on shares of ArriVent BioPharma from $42.00 to $29.00 and set a "buy" rating for the company in a research note on Wednesday. Guggenheim dropped their price objective on ArriVent BioPharma from $45.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ArriVent BioPharma in a research report on Friday, July 17th. Finally, HC Wainwright boosted their target price on shares of ArriVent BioPharma from $44.00 to $47.00 and gave the stock a "buy" rating in a research report on Monday, August 17th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $33.12.

ArriVent BioPharma Trading Up 6.9%

The company has a market capitalization of $795.44 million, a price-to-earnings ratio of -4.46 and a beta of 1.34. The company has a 50 day moving average price of $29.57 and a 200 day moving average price of $29.43.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.06). Equities analysts predict that ArriVent BioPharma, Inc. will post -4.11 earnings per share for the current year.

Institutional Trading of ArriVent BioPharma

Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP bought a new position in ArriVent BioPharma in the second quarter valued at approximately $59,000. Glenmede Trust Co. NA acquired a new position in ArriVent BioPharma in the 1st quarter valued at about $209,000. The Manufacturers Life Insurance Company acquired a new stake in ArriVent BioPharma during the first quarter worth approximately $209,000. Jupiter Topco LLC acquired a new stake in ArriVent BioPharma during the second quarter worth approximately $226,000. Finally, Arizona State Retirement System bought a new stake in ArriVent BioPharma in the 2nd quarter valued at $233,000. 9.48% of the stock is currently owned by institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent's lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.